echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Deck Pharmaceuticals obtained US FDA approval of ATG-101 (PD-L1/4-1BB double antibody) for the treatment of solid tumors and non-Hodgkin's lymphoma Phase I trial of new drug research application

    Deck Pharmaceuticals obtained US FDA approval of ATG-101 (PD-L1/4-1BB double antibody) for the treatment of solid tumors and non-Hodgkin's lymphoma Phase I trial of new drug research application

    • Last Update: 2021-12-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Shanghai and Hong Kong November 1, 2021/PRNewswire/ - Deqi Pharmaceutical Co.
    , Ltd.
    (abbreviated as a leading biopharmaceutical company dedicated to the development and commercialization of the world’s first and/or best-in-class blood and innovative tumor therapies "Deqi Pharmaceutical", Hong Kong Stock Exchange stock code: 6996.
    HK) today announced that the US Food and Drug Administration (FDA) has approved its ATG-101 New Drug Research Application (IND)
    .


    ATG-101 is a bispecific monoclonal antibody being developed by Deqi Pharmaceuticals for the treatment of metastatic or advanced solid tumors and B-cell non-Hodgkin's lymphoma (B-NHL)


    ATG-101 is the first innovative drug developed by Deqi Pharmaceutical's R&D team that has entered the clinic and has global rights and interests
    .


    This approval is the second clinical trial application approved by ATG-101 worldwide after the approval of Australia and the initiation of phase I clinical trials.


    As a new PD-L1/4-1BB bispecific antibody, ATG-101 can block the immunosuppressive PD-L1/PD-1 binding and conditionally activate the 4-1BB costimulatory signal, thereby activating anti-tumor Immune effector cells enhance safety while enhancing drug efficacy
    .


    ATG-101 has shown significant anti-tumor efficacy in animal models of immune checkpoint inhibitor resistance or recurrence, and has shown excellent safety in GLP toxicology studies


    "ATG-101 is expected to provide newer and more effective treatments for solid tumors and NHL patients who have received anti-PD-1 or anti-PD-L1 treatments that have relapsed or are drug-resistant.
    It is expected to meet a huge and ongoing Unmet medical needs,” said Dr.
    Mei Jianming, founder, chairman and CEO of Deqi Pharmaceuticals, “The approval of the clinical trial application for ATG-101 in the United States is an important milestone for Deqi Pharmaceuticals.

    ATG-101 The phase I dose-escalation clinical trial
    of Chemie is also underway in Australia, and it is expected that IND applications will be submitted in China this year .


    These fully demonstrate the strong execution of our team in different countries around the world, and further promote Deqi Pharmaceutical’s "Doctors have no boundaries, and innovation is forever.
    " Continue's vision


    About ATG-101

    ATG-101 is a new PD-L1/4-1BB bispecific antibody that is being developed for the treatment of metastatic/advanced solid tumors and B-cell non-Hodgkin’s lymphoma (B-NHL)
    .


    ATG-101 can simultaneously block PD-L1/PD-1 binding and activate 4-1BB costimulatory signals, thereby activating anti-tumor immune effector cells


    About Deqi Pharmaceutical

    Deqi Pharmaceutical Co.
    , Ltd.
    (abbreviated as "Deqi Pharmaceutical", Hong Kong Stock Exchange stock code: 6996.
    HK) is a leading R&D-driven biopharmaceutical company dedicated to providing the most advanced therapies and treatments for patients in Asia Pacific and even the world Tumors and other life-threatening diseases
    .


    Since its official operation in 2017, Deqi Pharmaceuticals has established a rich product pipeline that extends from pre-clinical to clinical stages through cooperative introduction and independent research and development


    Forward-looking statements

    The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article
    .


    Except as required by law, we have no obligation to update or publicly revise any forward-looking statements and unexpected events after the date of forward-looking statements, regardless of whether new information, future events or other circumstances appear


    Source: Deqi Pharmaceutical Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.